Clinical Trial: Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Safety Confirmatory Study of JC0498 (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
Brief Summary:
This is a multi-center, open label, study conducted to evaluate the safety of laronidase administered by intravenous drip infusion in Japanese patients with MPS I disease.
Following baseline evaluation, patients will receive weekly infusions of JC0498 at an intravenous dose of 100 units/kg. Patient safety will be monitored continuously throughout the trial. In addition, the effects of JC0498 treatment in this patient population will be assessed by periodically evaluating aspects of MPS I disease in patients at scheduled intervals over the duration of the trial.
Since patients may be eligible for the trial if they have received JC0498, a portion of the data may be captured retrospectively and recorded onto the case report forms (CRFs).
This study represents the first good clinical practice (GCP) effort to characterize MPS I in the Japanese population and evaluate the effects of JC0498 on disease manifestations.
Detailed Summary:
Sponsor: Genzyme, a Sanofi Company
Current Primary Outcome: Safety Evaluation [ Time Frame: Up to 73 Weeks ]
Original Primary Outcome: Safety assessment of JC0498 (laronidase)
Current Secondary Outcome: Urinary Glycosaminoglycan (GAG) Excretion [ Time Frame: Up to 73 Weeks ]
Original Secondary Outcome:
- Pharmacodynamic assessment of JC0498 (laronidase) with urinary glycosaminoglycan(GAG) excretion.
- Tertiary objective: Efficacy assessment of JC0498 (laronidase).
Information By: Sanofi
Dates:
Date Received: November 22, 2005
Date Started: December 2005
Date Completion:
Last Updated: February 4, 2014
Last Verified: February 2014